These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 7050190)

  • 1. Controversies in mycosis fungoides.
    Thiers BH
    J Am Acad Dermatol; 1982 Jul; 7(1):1-16. PubMed ID: 7050190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is there a role for epigenetic factors in the pathogenesis of epidermotropic cutaneous T-cell lymphomas (mycosis fungoides and Sézary syndrome)?
    Bachelez H
    Hematol J; 2001; 2(4):286-9. PubMed ID: 11920262
    [No Abstract]   [Full Text] [Related]  

  • 3. Leu-8/CD7 antigen expression by CD3+ T cells: comparative analysis of skin and blood in mycosis fungoides/Sézary syndrome relative to normal blood values.
    Wood GS; Hong SR; Sasaki DT; Abel EA; Hoppe RT; Warnke RA; Morhenn VB
    J Am Acad Dermatol; 1990 Apr; 22(4):602-7. PubMed ID: 1690762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Locomotion of T cells from patients with cutaneous T-cell lymphoma (Sézary syndrome and mycosis fungoides).
    Gupta S; Safai B; Edelson R; Parrott D; Good R
    Cell Immunol; 1980 Mar; 50(1):195-201. PubMed ID: 6967357
    [No Abstract]   [Full Text] [Related]  

  • 5. Cutaneous T cell lymphoma: mycosis fungoides, Sézary syndrome, and other variants.
    Edelson RL
    J Am Acad Dermatol; 1980 Feb; 2(2):89-106. PubMed ID: 6988470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mycosis fungoides in relation to environmental exposures and immune response: a case-control study.
    Whittemore AS; Holly EA; Lee IM; Abel EA; Adams RM; Nickoloff BJ; Bley L; Peters JM; Gibney C
    J Natl Cancer Inst; 1989 Oct; 81(20):1560-7. PubMed ID: 2795681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. OKT 9 reactivity in mycosis fungoides and large plaque (atrophic) parapsoriasis.
    McMillan EM; Wasik R; Peters S; Jackson I; Stoneking L; Everett MA
    Cancer; 1983 Apr; 51(8):1403-7. PubMed ID: 6337701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patch tests in Sézary syndrome and mycosis fungoides.
    Shupp DL; Winkelmann RK
    Contact Dermatitis; 1985 Sep; 13(3):180-5. PubMed ID: 4053598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pathogenesis of mycosis fungoides.
    Norris DA
    Clin Exp Dermatol; 1981 Jan; 6(1):77-87. PubMed ID: 7023759
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunopathogenesis of mycosis fungoides/Sézary syndrome (cutaneous T-cell lymphoma).
    Wong HK
    G Ital Dermatol Venereol; 2008 Dec; 143(6):375-83. PubMed ID: 19169210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Langerhans cells: involvement in the pathogenesis of mycosis fungoides.
    Rowden G; Lewis MG
    Br J Dermatol; 1976 Dec; 95(6):665-72. PubMed ID: 1009016
    [No Abstract]   [Full Text] [Related]  

  • 13. Do environmental factors play any role in the pathogenesis of mycosis fungoides and Sézary syndrome?
    Teixeira F; Ortiz-Plata A; Cortes-Franco R; Domínguez-Soto L
    Int J Dermatol; 1994 Nov; 33(11):770-2. PubMed ID: 7822078
    [No Abstract]   [Full Text] [Related]  

  • 14. [Sézary syndrome. Clinical, immunological and proliferative kinetics].
    Marosi L; Hofer F; Schwarzmeier J; Konrad K; Knapp W; Radaskiewicz T
    Acta Med Austriaca; 1979; 6(5):237-40. PubMed ID: 318012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous T-cell lymphoma: a review.
    Winkler CF; Bunn PA
    Crit Rev Oncol Hematol; 1983; 1(1):49-92. PubMed ID: 6083835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New aspects of the clinicopathological features and treatment of mycosis fungoides and Sézary syndrome.
    Furue M; Kadono T
    J Dermatol; 2015 Oct; 42(10):941-4. PubMed ID: 26432429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal Langerhans' cell densities influence survival in mycosis fungoides and Sézary syndrome.
    Meissner K; Michaelis K; Rehpenning W; Löning T
    Cancer; 1990 May; 65(9):2069-73. PubMed ID: 2196990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pathogenesis of mycosis fungoides.
    Girardi M; Heald PW; Wilson LD
    N Engl J Med; 2004 May; 350(19):1978-88. PubMed ID: 15128898
    [No Abstract]   [Full Text] [Related]  

  • 19. Lymph node involvement by mycosis fungoides and Sézary syndrome mimicking angioimmunoblastic T-cell lymphoma.
    LeBlanc RE; Lefterova MI; Suarez CJ; Tavallaee M; Kim YH; Schrijver I; Kim J; Gratzinger D
    Hum Pathol; 2015 Sep; 46(9):1382-9. PubMed ID: 26193796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotype of cells involved in mycosis fungoides and Sézary syndrome (blood and skin lesions): immunomorphological study with monoclonal antibodies.
    Schmitt D; Souteyrand P; Brochier J; Czernielewski J; Thivolet J
    Acta Derm Venereol; 1982; 62(3):193-9. PubMed ID: 6179357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.